FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550768619> ?p ?o ?g. }

• W2550768619 endingPage "87322" @default.
• W2550768619 startingPage "87312" @default.
• W2550768619 abstract "// Weige Tan 1, 2, * , Wei Luo 1, * , Weijuan Jia 1 , Gehao Liang 1 , Xinhua Xie 3 , Wenbo Zheng 2 , Erwei Song 1, 4 , Fengxi Su 1 , Chang Gong 1 1 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China 2 Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China 3 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 4 Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou, China * These authors have contributed equally to this work Correspondence to: Chang Gong, email: changgong282@163.com Fengxi Su, email: fengxisu@vip.163.com Keywords: breast cancer, pathologic complete response, neoadjuvant chemotherapy, Nottingham prognostic index, IHC4 Received: July 13, 2016      Accepted: November 07, 2016      Published: November 24, 2016 ABSTRACT Pathologic complete response (pCR) prediction after neoadjuvant chemotherapy (NAC) is important for clinical decision-making in breast cancer. This study investigated the predictive value of Nottingham prognostic index (NPI), Immunohistochemical four (IHC4) score and a new predictive index combined with them in estrogen-positive (ER+) breast cancer following NAC. We retrospectively gathered clinical data of 739 ER+ breast cancer patients who received NAC from two cancer centers. We developed a new predictive biomarker named NPI+IHC4 to predict pCR in ER+ breast cancer in a training set (n=443) and validated it in an external validation set (n=296). The results showed that a lower IHC4 score, NPI and NPI+IHC4 were significantly associated a high pCR rate in the entire cohort. In the study set, NPI+IHC4 showed a better sensitivity and specificity for pCR prediction (AUC 0.699, 95% CI 0.626-0.772) than IHC4 score (AUC 0.613, 95% CI 0.533-0.692), NPI (AUC 0.576, 95% CI 0.494-0.659), tumor size (AUC 0.556, 95% CI 0.481-0.631) and TNM stage (AUC 0.521, 95% CI 0.442-0.601). In the validation set, NPI+IHC4 had a better predictive value for pCR (AUC 0.665, 95% CI 0.579-0.751) than IHC4 score or NPI alone. In addition, ER+ patients with lower IHC4, NPI and NPI+IHC4 scores had significantly better DFS in both study and validation sets. In summary, NPI+IHC4 can predict pCR following NAC and prognosis in ER+ breast cancer, which is cost-effect and potentially more useful in guiding decision-making regarding NAC in clinical practice. Further validation is needed in prospective clinical trials with larger cohorts of patients." @default.
• W2550768619 created "2016-11-30" @default.
• W2550768619 creator A5012343356 @default.
• W2550768619 creator A5021387235 @default.
• W2550768619 creator A5035759104 @default.
• W2550768619 creator A5049156370 @default.
• W2550768619 creator A5057006919 @default.
• W2550768619 creator A5065794355 @default.
• W2550768619 creator A5068496245 @default.
• W2550768619 creator A5084864439 @default.
• W2550768619 creator A5088111638 @default.
• W2550768619 date "2016-11-24" @default.
• W2550768619 modified "2023-10-17" @default.
• W2550768619 title "A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer" @default.
• W2550768619 cites W1555003755 @default.
• W2550768619 cites W1923080481 @default.
• W2550768619 cites W1960732871 @default.
• W2550768619 cites W1963505593 @default.
• W2550768619 cites W1969622989 @default.
• W2550768619 cites W1973803589 @default.
• W2550768619 cites W1989037008 @default.
• W2550768619 cites W1989222913 @default.
• W2550768619 cites W1995859582 @default.
• W2550768619 cites W2010871781 @default.
• W2550768619 cites W2017098623 @default.
• W2550768619 cites W2024298772 @default.
• W2550768619 cites W2054270840 @default.
• W2550768619 cites W2057084727 @default.
• W2550768619 cites W2057559260 @default.
• W2550768619 cites W2073631512 @default.
• W2550768619 cites W2075894019 @default.
• W2550768619 cites W2084077572 @default.
• W2550768619 cites W2085177488 @default.
• W2550768619 cites W2092181138 @default.
• W2550768619 cites W2099005045 @default.
• W2550768619 cites W2105219549 @default.
• W2550768619 cites W2105882193 @default.
• W2550768619 cites W2113344831 @default.
• W2550768619 cites W2113656973 @default.
• W2550768619 cites W2116522870 @default.
• W2550768619 cites W2125794840 @default.
• W2550768619 cites W2147415463 @default.
• W2550768619 cites W2152121590 @default.
• W2550768619 cites W2153158488 @default.
• W2550768619 cites W2157250162 @default.
• W2550768619 cites W2157840751 @default.
• W2550768619 cites W2172045238 @default.
• W2550768619 cites W2407007268 @default.
• W2550768619 doi "https://doi.org/10.18632/oncotarget.13549" @default.
• W2550768619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5349990" @default.
• W2550768619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27894097" @default.
• W2550768619 hasPublicationYear "2016" @default.
• W2550768619 type Work @default.
• W2550768619 sameAs 2550768619 @default.
• W2550768619 citedByCount "10" @default.
• W2550768619 countsByYear W25507686192017 @default.
• W2550768619 countsByYear W25507686192019 @default.
• W2550768619 countsByYear W25507686192020 @default.
• W2550768619 countsByYear W25507686192021 @default.
• W2550768619 countsByYear W25507686192022 @default.
• W2550768619 crossrefType "journal-article" @default.
• W2550768619 hasAuthorship W2550768619A5012343356 @default.
• W2550768619 hasAuthorship W2550768619A5021387235 @default.
• W2550768619 hasAuthorship W2550768619A5035759104 @default.
• W2550768619 hasAuthorship W2550768619A5049156370 @default.
• W2550768619 hasAuthorship W2550768619A5057006919 @default.
• W2550768619 hasAuthorship W2550768619A5065794355 @default.
• W2550768619 hasAuthorship W2550768619A5068496245 @default.
• W2550768619 hasAuthorship W2550768619A5084864439 @default.
• W2550768619 hasAuthorship W2550768619A5088111638 @default.
• W2550768619 hasBestOaLocation W25507686191 @default.
• W2550768619 hasConcept C121608353 @default.
• W2550768619 hasConcept C126322002 @default.
• W2550768619 hasConcept C143998085 @default.
• W2550768619 hasConcept C2776694085 @default.
• W2550768619 hasConcept C2779740036 @default.
• W2550768619 hasConcept C2781197716 @default.
• W2550768619 hasConcept C29456083 @default.
• W2550768619 hasConcept C530470458 @default.
• W2550768619 hasConcept C55493867 @default.
• W2550768619 hasConcept C71924100 @default.
• W2550768619 hasConcept C84606932 @default.
• W2550768619 hasConcept C86803240 @default.
• W2550768619 hasConceptScore W2550768619C121608353 @default.
• W2550768619 hasConceptScore W2550768619C126322002 @default.
• W2550768619 hasConceptScore W2550768619C143998085 @default.
• W2550768619 hasConceptScore W2550768619C2776694085 @default.
• W2550768619 hasConceptScore W2550768619C2779740036 @default.
• W2550768619 hasConceptScore W2550768619C2781197716 @default.
• W2550768619 hasConceptScore W2550768619C29456083 @default.
• W2550768619 hasConceptScore W2550768619C530470458 @default.
• W2550768619 hasConceptScore W2550768619C55493867 @default.
• W2550768619 hasConceptScore W2550768619C71924100 @default.
• W2550768619 hasConceptScore W2550768619C84606932 @default.
• W2550768619 hasConceptScore W2550768619C86803240 @default.
• W2550768619 hasIssue "52" @default.
• W2550768619 hasLocation W25507686191 @default.
• W2550768619 hasLocation W25507686192 @default.

• next